Investors & Media

Corporate Profile

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has four programs in active clinical development.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News & Events

News Releases

November 13, 2023

NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®

November 7, 2023

NGM Bio to Participate in Upcoming Investor Conferences

November 2, 2023

NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Contact Information

investor relations

ir@ngmbio.com

media relations

media@ngmbio.com